Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1826 results
September 2019
-
Press release
Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)
Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent… -
Press release
Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years… -
Press release
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer
Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy… -
Press release
Novartis study shows migraine support in the workplace can improve employee quality of life
Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] … -
Press release
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS… -
Press release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1… -
Press release
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
August 2019
-
Story Patient Perspectives
Living with HFpEF – a patient’s story
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
-
Ad hoc release
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary… -
Featured News
Blood Cancer Awareness Month - Cutting Edge Innovation in Hematology
-
Featured News
Impact Measurement and Valuation
Novartis joins seven global companies to found the Value Balancing Alliance
-
Press release
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…